LXRX - Lexicon resubmits FDA application for sotagliflozin for type 1 diabetes
2024-06-21 10:07:49 ET
More on Lexicon Pharmaceuticals
- Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much
- Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Call Transcript
- Lexicon Pharmaceuticals Q1 2024 Earnings Preview
- Seeking Alpha’s Quant Rating on Lexicon Pharmaceuticals
- Historical earnings data for Lexicon Pharmaceuticals